Accessibility Menu
 
Alterity Therapeutics logo

Alterity Therapeutics

(ASX) ATH

Current Price$0.01
Market Cap$108.75M
Since IPO (2000)-99%
5 Year-67%
1 Year+25%
1 Month+11%

Alterity Therapeutics Financials at a Glance

Market Cap

$108.75M

Revenue (TTM)

$7.56M

Net Income (TTM)

$34.38M

EPS (TTM)

$-0.00

P/E Ratio

-6.67

Dividend

$0.00

Beta (Volatility)

-0.12 (Low)

Price

$0.01

Volume

3,432,913

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.01 - $0.02

ATH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alterity Therapeutics

Industry

Biotechnology

Employees

9

CEO

David A. Stamler, MD

Headquarters

Melbourne, VIC 3000, AU

ATH Financials

Key Financial Metrics (TTM)

Gross Margin

97%

Operating Margin

-5%

Net Income Margin

-4%

Return on Equity

-47%

Return on Capital

-37%

Return on Assets

-26%

Earnings Yield

-14.99%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$108.75M

Shares Outstanding

10.88B

Volume

3.43M

Avg. Volume

8.38M

Financials (TTM)

Gross Profit

$5.31M

Operating Income

$14.57M

EBITDA

$14.63M

Operating Cash Flow

$11.45M

Capital Expenditure

$0.00

Free Cash Flow

$11.45M

Cash & ST Invst.

$40.66M

Total Debt

$155.46K

Alterity Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$57.89K

-103.2%

Gross Margin

0.00%

N/A

Market Cap

$108.75M

N/A

Market Cap/Employee

$10.88M

N/A

Employees

10

N/A

Net Income

$9.62M

-47.8%

EBITDA

$13.00M

-56.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Net Cash

$49.04M

+306.4%

Accounts Receivable

$6.84M

+17.9%

Inventory

$0.00

N/A

Long Term Debt

$130.92K

+71.1%

Short Term Debt

$32.99K

-81.6%

Return on Assets

-25.63%

N/A

Return on Invested Capital

-37.08%

N/A

Free Cash Flow

$0.00

+100.0%

Operating Cash Flow

$10.62M

-136.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ILA.AXIsland Pharmaceuticals Limited
$0.40+6.67%
ALA.AXArovella Therapeutics Limited
$0.08-5.00%
RCE.AXRecce Pharmaceuticals Ltd
$0.51+5.21%
BIO.AXBiome Australia Limited
$0.29-1.69%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$94.48-0.00%
NOKNokia
$12.91+0.04%
SOFISoFi Technologies
$16.10+0.04%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.63+0.10%

Questions About ATH

What is the current price of Alterity Therapeutics?

Alterity Therapeutics is trading at A$0.01 per share.

What is the 52-week range for Alterity Therapeutics?

Over the past 52 weeks, Alterity Therapeutics has traded between A$0.01 and A$0.02.

How much debt does Alterity Therapeutics have?

As of the most recent reporting period, Alterity Therapeutics reported total debt of $155,457.

How much cash does Alterity Therapeutics have on hand?

Alterity Therapeutics reported $33.16M in cash and cash equivalents in its most recent financial results.

What is Alterity Therapeutics’s dividend yield?

Alterity Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.